Evidence map›Paper›PMID 34695727›Full record

ReviewCurrent opinion in immunology2021

Maximizing insights from monogenic immune disorders.

Anis Barmada, Anjali Ramaswamy, Carrie L Lucas

Abstract readReview
In one paragraph

Review in Current opinion in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anis BarmadaYale University School of Medicine, Department of Immunobiology, New Haven, CT, USA.
Anjali RamaswamyYale University School of Medicine, Department of Immunobiology, New Haven, CT, USA.
Carrie L LucasYale University School of Medicine, Department of Immunobiology, New Haven, CT, USA. Electronic address: Carrie.Lucas@yale.edu.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Mechanisms of mucosal autoinflammation elucidated by a novel monogenic transcription factor defectR01AI150913 · NIAID · YALE UNIVERSITY · PI LUCAS, CARRIE L. · 2021 to 2025
$2.9M
Novel roles for the DNA damage response kinase CHK1 in TCR/ITAM signalingR01AI138141 · NIAID · YALE UNIVERSITY · PI LUCAS, CARRIE L. · 2018 to 2022
$2.4M
Mechanisms of immune dysregulation in human PI3Kgamma deficiencyR21AI144315 · NIAID · YALE UNIVERSITY · PI LUCAS, CARRIE L. · 2020 to 2021
$830k
NCATS NIH HHS UL1 TR001863NIAID NIH HHS R01 AI138141NIAID NIH HHS R01 AI150913NIAID NIH HHS R21 AI144315
6 · The paper itself

Abstract

Monogenic immune disorders provide unprecedented insights into the consequences of disrupting single genes in humans, thereby informing our understanding of fundamental immune function and disease. Genomics has accelerated monogenic disease discovery while also revealing the complexity of human disease, where several factors beyond the genome can govern pathogenesis. At this juncture, the optimal path forward will focus on maximizing basic and translational immunology insights from these disorders. This pursuit will be most direct and impactful if human disease gene discovery is paired with mechanistic studies employing integrative omics and mouse modeling to leverage their unique strengths.

Indexed as

AnimalsDisease Models, AnimalGenetic TestingGenomicsHumansImmune System DiseasesMiceProteomicsTranslational Research, Biomedical

Identifiers

PMID34695727
PMCPMC8915947

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.